Quanterix Corporation Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Quanterix Corporation (QTRX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $14.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-10
- Quanterix Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $6.39M, a 66.33% decline year-over-year.
- Quanterix Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $18.97M.
- Quanterix Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$128.76M.
- Quanterix Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$9.41M.
- Quanterix Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$27.71M.
- Quanterix Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$116.97M.
- Quanterix Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$164.61M.
- Quanterix Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$57.39M, a 126.48% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.40M 10-Q · filed 2026-08-10 | |||||||
| 2026-03-31 | $6.39M 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | -$27.71M 10-K · filed 2026-03-02 | |||||||
| 2025-09-30 | -$19.19M 10-Q · filed 2025-11-10 | |||||||
| 2025-06-30 | $74.76M 10-Q · filed 2026-08-10 | |||||||
| 2025-03-31 | $18.97M 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | -$116.97M 10-K · filed 2026-03-02 | |||||||
| 2024-09-30 | -$145.10M 10-Q · filed 2025-11-10 | |||||||
| 2024-06-30 | -$127.06M 10-Q · filed 2025-08-07 | |||||||
| 2024-03-31 | -$128.76M 10-Q · filed 2025-05-12 | |||||||
| 2023-12-31 | -$164.61M 10-K · filed 2026-03-02 | |||||||
| 2023-09-30 | -$137.25M 10-K/A · filed 2024-12-26 | -$137.20M 10-Q · filed 2023-11-08 | ||||||
| 2023-06-30 | -$9.05M 10-K/A · filed 2024-12-26 | -$8.96M 10-Q · filed 2023-08-08 | ||||||
| 2023-03-31 | -$9.41M 10-K/A · filed 2024-12-26 | -$9.09M 10-Q · filed 2023-05-09 | ||||||
| 2022-12-31 | -$57.39M 10-K · filed 2025-03-17 | -$57.17M 10-K · filed 2024-02-29 | ||||||
| 2022-09-30 | -$52.42M 10-K/A · filed 2024-12-26 | -$52.20M 10-Q · filed 2023-11-08 | ||||||
| 2022-06-30 | -$34.35M 10-K/A · filed 2024-12-26 | -$34.38M 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | -$21.59M 10-K/A · filed 2024-12-26 | -$21.59M 10-Q · filed 2023-05-09 | ||||||
| 2021-12-31 | $216.78M 10-K/A · filed 2024-12-26 | $216.55M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |